Mantle Cell Lymphoma Excellence Forum

Mantle Cell Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Assessing the Optimal Ki-67 Cut-Off for Outcome Prediction Among Patients With Newly Diagnosed Mantle Cell Lymphoma

12/10/2023

Narendranath Epperla , MD, MS;

At the 65th ASH Annual Meeting, Narendranath Epperla, MD, MS, shared insights on an optimal Ki-67 cut-off for patients with newly diagnosed mantle cell lymphoma, which was found to be prognostic for progression-free survival, but not overall...

At the 65th ASH Annual Meeting,...

12/10/2023

Oncology

Videos

Evaluating Prognostic Factors for Mantle Cell Lymphoma

11/15/2023

Jia Ruan , MD, PhD;

Jia Ruan, MD, PhD, discusses important factors to consider in determining mantle cell lymphoma prognosis, including the utilization of measurement tools like MIPI and genetic mutation profile data.

Jia Ruan, MD, PhD, discusses...

11/15/2023

Oncology

Videos

Long-Term Updates on Chemotherapy-Free Lenalidomide Plus Rituximab Treatment for MCL

11/03/2023

Jia Ruan , MD, PhD;

Jia Ruan, MD, PhD, shares 9-year follow-up findings from a phase 2 trial on the outcomes of chemotherapy-free lenalidomide plus rituximab combination therapy among patients with mantle cell lymphoma.

Jia Ruan, MD, PhD, shares 9-year...

11/03/2023

Oncology

Videos

Recent Breakthroughs in Therapies for Patients With Mantle Cell Lymphoma

10/23/2023

Tycel Phillips ;

Tycel Phillips, MD, discusses 2 recent advancements in the treatment landscape of mantle cell lymphoma, including the use of BTK inhibitor pirtobrutinib, and CAR T-cell therapy treatment lisocabtagene maraleucel.

Tycel Phillips, MD, discusses 2...

10/23/2023

Oncology

Videos

Exploring the Efficacy of BTK Inhibitor Glofitamab Among Patients With R/R MCL

10/23/2023

Tycel Phillips ;

Tycel Phillips, MD, reports updated findings from a phase 1/2 trial examining the efficacy and safety of glofitamab, a BTK inhibitor, among patients with heavily pretreated R/R mantle cell lymphoma.

Tycel Phillips, MD, reports...

10/23/2023

Oncology

Quiz

Venetoclax, Lenalidomide, and Rituximab Triplet Combination for MCL

10/18/2023

True or False: Findings from a single-arm study on the addition of venetoclax to lenalidomide and rituximab treatment for patients with previously untreated mantle cell lymphoma indicated that patients treated with this triplet combination...

True or False: Findings from a...

10/18/2023

Oncology

Quiz

Novel Therapeutic Target FGFR1 for Patients With MCL

10/10/2023

True or False: Findings from a study aiming to identify a regulator that directly contributes to the clinical outcomes of mantle cell lymphoma (MCL) indicated that fibroblast growth factor receptor-1 (FGFR1) overexpression in preclinical...

True or False: Findings from a...

10/10/2023

Oncology

Quiz

Significance of DTI for MCL Treatment Outcomes

09/25/2023

True or False: According to findings from a pooled analysis of 3 datasets assessing the potential significance of diagnosis to treatment interval (DTI) for the prognosis of mantle cell lymphoma, patients with shorter DTI were noted to have...

True or False: According to...

09/25/2023

Oncology

Videos

Addition of Venetoclax to Lenalidomide and Rituximab Therapy for Patients With Previously Untreated MCL

09/22/2023

Kami J. Maddocks , MD;

Kami J. Maddocks, MD, discusses results from a single-arm study on the addition of venetoclax to a lenalidomide and rituximab regimen for patients with previously untreated mantle cell lymphoma.

Kami J. Maddocks, MD, discusses...

09/22/2023

Oncology

Videos

Exploring the Role of FGFR1 as a Therapeutic Target Among Patients With MCL

09/22/2023

Narendranath Epperla , MD, MS;

Narendranath Epperla, MD, MS, discusses the current research on fibroblast growth factor receptor-1 as an up-and-coming and viable therapeutic target for patients with mantle cell lymphoma.

Narendranath Epperla, MD, MS,...

09/22/2023

Oncology

Recent News

Conference Insider

Dr Martin Discusses How to Approach MCL

03/23/2022

Emily Bader ;

Peter Martin, MD, discusses how to approach MCL, including what’s been learned so far and what’s to be expected, at the virtual Great Debates & Updates in Hematologic Malignancies.

Peter Martin, MD, discusses how...

03/23/2022

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology